Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
CC transcript

MAXCYTE, INC. (MXCT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
08/09/2023 8-K Quarterly results
05/10/2023 8-K Quarterly results
03/28/2023 8-K Quarterly results
03/15/2023 8-K Quarterly results
03/06/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
12/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "MaxCyte Appoints Patrick J. Balthrop as Non-Executive Director Rockville, MD, 1 December, 2022: MaxCyte, Inc., , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announces the appointment of Patrick J. Balthrop, Sr. to the company’ s Board of Directors as non-executive director with immediate effect. Mr. Balthrop is also appointed as non-executive member of the Nominating and Corporate Governance Committee. Mr. Balthrop has more than 35 years of experience in the healthcare sector, particularly in the life sciences segments of diagnostics, life science tools, and medical devices. He was CEO, Presiden..."
11/09/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
04/12/2022 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue GAITHERSBURG, MD, April 12, 2022 — MaxCyte, Inc., , a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that Amanda Murphy has resigned from her position as Chief Financial Officer, effective as of April 15, 2022, to pursue other interests. Ron Holtz, current Senior Vice President and Chief Accounting Officer, has been named Interim Chief Financial Officer effective upon Ms. Murphy’ s departure. Following her departure, Ms. Murphy intends to provide consulting services to ..."
03/22/2022 8-K Quarterly results
01/24/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results"
11/10/2021 8-K Quarterly results
Docs: "MaxCyte Reports Third Quarter Financial Results GAITHERSBURG, MD, November 10, 2021 — MaxCyte, Inc., , a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced third quarter ended September 30, 2021 financial results. Third Quarter and Recent Highlights · Total revenue was $10.1 million in the third quarter of 2021, representing 50% growth compared to the same period in 2020. · Excluding Strategic Platform License Program-related revenue, revenue from cell therapy customers was $6.2 million for the third quarter, an increase of 38% compared to the same period in 2020. · SPL Program-r..."
11/02/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
10/01/2021 8-K Quarterly results
09/17/2021 8-K Quarterly results
08/04/2021 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Amended and Restated Bylaws of the Registrant"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy